Acorda Therapeutics's EBIT per Share for the
three
months ended in Dec. 2023 was $-198.61.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $-212.62.
During the past 3 years, the average EBIT per Share Growth Rate was 55.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Acorda Therapeutics's EBIT per Share or its related term are showing as below:
ACORQ'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -61.4 Med: 38 Max: 80
Current: 55.7
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Acorda Therapeutics was 80.00% per year. The lowest was -61.40% per year. And the median was 38.00% per year.
ACORQ's 3-Year EBIT Growth Rate is ranked better than 90.71% of 850
companies
in the Drug Manufacturers industry
Industry Median: 7.95
vs ACORQ: 55.70
Acorda Therapeutics EBIT per Share Historical Data
The historical data trend for Acorda Therapeutics's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-212.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acorda Therapeutics (OTCPK:ACORQ) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Acorda Therapeutics EBIT per Share Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your 